The temporal integration window can be described as the critical period during which the brain synthesizes sensory inputs to form a coherent perceptual experience. This processing interval is crucial for normal cognitive function, influencing everything from basic sensory perception to complex decision-making. The new research demonstrates that deviations in TIW are not merely incidental but systematically vary among healthy individuals, those clinically at high risk (CHR) for psychosis, and first-episode schizophrenia (FES) patients. This gradient of alteration underscores TIW as a potential marker reflecting the transitional phases of psychotic illness.

To discern these differences in TIW, the study employed sophisticated neuropsychological assays that measured how participants integrated sensory stimuli over time. Healthy controls (HC) showed a relatively narrow and consistent TIW, indicative of efficient sensory integration. In contrast, CHR individuals exhibited an intermediate expansion of this window, while FES groups revealed a significantly prolonged TIW. Such prolongation may underlie the sensory and cognitive disruptions hallmarking psychotic disorders, wherein the brain struggles to bind and interpret sensory information accurately.

Crucially, the study unveiled robust correlations between TIW measures and cognitive performance across domains frequently impaired in psychosis—attention, working memory, and executive function. These findings emphasize the intricate link between sensory integration processes and higher-order cognition, suggesting that altered TIW could serve not just as a diagnostic metric but also as a proxy for functional impairment. This dual utility enhances its value as a clinical tool, bridging the traditional gap between symptom observation and neurobiological measurement.

The neurophysiological underpinnings of an expanded TIW in psychosis risk remain a subject of intense investigation. Emerging evidence points toward disruptions in cortical oscillatory dynamics—rhythmic brain activity patterns that coordinate sensory processing and cognitive integration. Alterations in gamma and theta frequency bands, critical for temporal binding and information flow, might distort the temporal precision necessary for normal TIW. This pathophysiological insight enriches our understanding of the disease mechanism at a fundamental level.

Current diagnostic practices for schizophrenia spectrum disorders rely heavily on clinical interviews and behavioral assessments, which, while valuable, are inherently subjective and often detect the illness after substantial functional decline. The introduction of an objective, quantifiable biomarker such as TIW could revolutionize this paradigm, enabling earlier and more precise identification of at-risk individuals. Early diagnosis is a critical window for intervention, when neuroplasticity is more amenable to therapeutic modulation, potentially preventing full disease manifestation.

The researchers emphasize the importance of longitudinal cohort studies to validate TIW’s predictive power over time. Tracking at-risk individuals through the prodromal phase into possible disease onset would clarify the temporal dynamics between TIW alterations and psychosis development. Such data could refine risk stratification models, personalize treatment approaches, and guide preventive strategies in clinical psychiatry.

Beyond prognosis, this sensory integration marker may also serve as an outcome measure for intervention efficacy. Treatments—pharmacological or cognitive remediation—that normalize TIW could demonstrate objective benefits, providing a biomarker-guided framework for clinical trials. This aligns with the broader movement toward precision medicine in mental health, tailoring therapies based on individual neurobiological profiles rather than symptom clusters alone.

The broader implications of TIW research extend beyond psychosis. Sensory integration abnormalities are implicated in diverse neuropsychiatric conditions, including autism spectrum disorders and mood disorders. Thus, understanding the modulation of temporal sensory processing windows may unlock cross-diagnostic insights, enriching neurodevelopmental and neurodegenerative disorder models. This could stimulate innovative multimodal interventions targeting sensory-cognitive pathways.

Technological advances were pivotal in this study’s success. High-resolution temporal neuroimaging and electrophysiological measurements facilitated precise quantification of TIW. Moreover, computational modeling of sensory integration dynamics allowed researchers to simulate pathological states and predict cognitive consequences. Such interdisciplinary approaches marry neuroscience, psychology, and data science, embodying the future of psychiatric biomarker research.

While TIW holds transformative potential, challenges lie ahead in translating these findings into clinical practice. Standardization of assessment protocols, ensuring accessibility, and training clinicians in interpreting TIW metrics are crucial steps. Additionally, ethical considerations about predictive testing in asymptomatic populations require thoughtful discourse, balancing benefits against potential stigma and psychological impacts.

In conclusion, this innovative research heralds a new era where temporal sensory integration metrics could become a cornerstone of early psychosis detection and personalized psychiatry. TIW exemplifies how delving into the brain’s fundamental temporal processing can illuminate the elusive mechanisms of mental illness and pave the way for better prevention and treatment paradigms.

As psychiatry strides forward in the 21st century, integrating neuropsychological markers like TIW into diagnostic and therapeutic frameworks promises to transform our approach from reactive symptom management to proactive brain health stewardship. The anticipation now rests on further studies that will confirm and expand upon these pioneering findings, ultimately bringing precision neuroscience from the lab bench to the patient bedside.

This research not only advances our scientific comprehension of schizophrenia spectrum disorders but also ignites hope for those facing the uncertainty of emerging psychosis. By harnessing the temporal integration window, scientists and clinicians edge closer to unraveling the enigma of psychosis, offering a beacon for early intervention and improved quality of life.

———

Subject of Research:
Article Title:
Article References:
Lin, S., Tian, L., Tan, Wh. et al. Temporal integration window of sensory processing as a neuropsychological marker for clinical high risk of psychosis. Schizophr 11, 132 (2025). https://doi.org/10.1038/s41537-025-00672-4
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41537-025-00672-4
Keywords: temporal integration window, sensory processing, neuropsychological marker, psychosis, schizophrenia spectrum, early diagnosis, cognitive impairment

Psychosis, characterized by profound disruptions in perception, thought processes, and emotional responsiveness, often emerges after subtle cognitive and behavioral changes. Early identification of these precursors is pivotal because it opens a therapeutic window where intervention can drastically alter disease trajectories. However, traditional clinical interviews and self-report scales have been limited by their subjective nature and variability in predictive accuracy. The new battery, meticulously engineered to be sensitive to underlying symptom mechanisms, offers a paradigm shift by anchoring assessment in objective, neurocognitive performance measures.

Central to the team’s strategy was the recognition that psychosis at-risk states manifest through distinct neurocognitive impairments closely tied to specific symptom domains. To this end, the researchers selected a suite of tasks that probe sensory processing, reward learning, working memory, and executive function, each domain previously implicated in psychotic disorders. This multi-dimensional task battery not only captures a more holistic profile of the individual’s cognitive architecture but also allows for granular analysis of which neural circuits may be faltering as risk escalates.

The research design incorporated a robust sample of individuals clinically identified as high risk for psychosis, alongside control groups. Participants underwent the battery of tasks, producing rich datasets of reaction times, error rates, and adaptive learning trajectories. Advanced statistical modeling techniques were then leveraged to discern patterns predictive of psychosis conversion. These models revealed that subtle deficits in reward prediction error signaling and working memory accuracy emerged as strong harbingers of symptom development, showcasing the battery’s predictive potency.

Importantly, this approach does not only provide a binary risk estimation but maps a nuanced continuum of risk states, reflecting variations in symptom severity and cognitive dysfunction. This gradated assessment is vital for tailoring interventions, as it highlights specific mechanistic targets rather than treating psychosis risk as a homogeneous clinical category. For example, individuals exhibiting pronounced deficits in executive control may benefit more from cognitive remediation, while those with abnormal sensory prediction errors might be candidates for neurofeedback or pharmacological modulation.

The implications of these findings extend beyond diagnostics. By elucidating the cognitive architecture underlying early psychotic symptoms, the task battery offers a window into disease pathophysiology. The integration of behavioral data with putative neural substrates encourages a move towards precision psychiatry, where interventions can be guided by measurable cognitive signatures rather than solely symptom-based heuristics. This objective, mechanism-driven approach promises enhanced efficacy and reduced side effects in treatment plans.

Moreover, the portability and scalability of such a battery create exciting possibilities for widespread clinical adoption. Designed as computerized tasks with standardized administration protocols, they are adaptable across clinical settings globally, including low-resource environments where psychosis burden is high but specialized assessment tools are scarce. This democratization of early detection could have profound public health impacts, especially if combined with mobile health technologies for remote monitoring.

The research team also acknowledges the potential to extend this battery for longitudinal tracking of at-risk individuals, enabling dynamic monitoring of cognitive changes over time. Such temporal resolution could inform personalized treatment adjustments and shed light on the trajectories that lead some individuals from risk to frank psychosis while others remain resilient. The study sets the stage for future investigations integrating neuroimaging or genetic data to create multimodal predictive models with even greater precision.

Still, the authors caution that while promising, this battery is not a diagnostic tool in isolation. It is best conceptualized as a complementary measure integrated within a broader clinical framework. The complexity of psychosis etiology necessitates combining cognitive assessments with environmental, genetic, and phenomenological data to capture the full risk profile. Future iterations of the battery might integrate patient-reported outcomes or real-world functional measures, enhancing ecological validity.

In terms of underlying neurobiology, the reported deficits align with emerging models that emphasize dysregulated dopaminergic signaling and disrupted cortical connectivity as key drivers of psychosis onset. Tasks sensitive to reward processing directly probe dopamine-mediated learning mechanisms, while working memory impairments reflect prefrontal cortex dysfunction. Thus, the battery bridges behavioral phenotyping with neurochemical hypotheses, facilitating translational research pathways.

Intriguingly, the study also highlights individual variability in task performance profiles, challenging the notion of psychosis risk as a monolithic entity. Some participants demonstrated isolated sensory processing anomalies, while others exhibited combined reward and executive deficits. This heterogeneity underscores the necessity for personalized diagnostic tools and tailored interventions, further supporting the paradigm shift towards individualized psychiatry.

The authors advocate for the integration of such task batteries into early intervention services, emphasizing that reliable identification of high-risk individuals is just the first step. Equally important is the deployment of targeted therapies informed by the cognitive mechanisms revealed through this approach. Cognitive remediation, neuromodulation, and pharmacotherapy tailored to the implicated symptom domains may improve outcomes far beyond what is possible with uniform treatment strategies.

Beyond clinical utility, the conceptual framework presented reinforces the merit of mechanistic thinking in psychiatry, moving away from purely symptom-based classification systems towards process-oriented models. By mapping symptom dimensions onto distinct cognitive impairments, this research aligns with initiatives like the Research Domain Criteria (RDoC) aimed at redefining mental disorders based on neurobiological substrates.

The promising results invite research in related domains as well. For instance, similar task batteries might be adapted to identify risk for other neuropsychiatric conditions such as bipolar disorder or major depression, which share overlapping cognitive disruptions. Cross-diagnostic applications could catalyze unified models of psychopathology that transcend traditional diagnostic silos.

Finally, this work symbolizes a beacon of progress towards precision mental health care in a field often criticized for its slow translational pace. Utilizing rigorous behavioral paradigms informed by pathophysiology not only enhances scientific understanding but also directly serves patient care goals. The potential to intervene strategically before irreversible illness onset envisions a future in which devastating psychiatric disorders are not only treatable but also preventable.

As mental health researchers and clinicians digest these findings, the field stands on the cusp of implementing a new generation of objective, mechanistically targeted diagnostic tools. With further validation, refinement, and integration into clinical practice, such task batteries could revolutionize early psychosis detection, reduce disease burden, and improve countless lives worldwide.

Subject of Research: Identification of individuals at clinical high risk for psychosis using mechanistically informed cognitive and behavioral tasks.

Article Title: Identifying individuals at clinical high risk for psychosis using a battery of tasks sensitive to symptom mechanisms.

Article References:
Williams, T.F., Gold, J.M., Waltz, J.A. et al. Identifying individuals at clinical high risk for psychosis using a battery of tasks sensitive to symptom mechanisms. Transl Psychiatry 15, 311 (2025). https://doi.org/10.1038/s41398-025-03539-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03539-5

At the core of this innovative endeavor lies the exploitation of polygenic scores, which amalgamate the cumulative effect of numerous genetic variants associated not only with psychosis but a spectrum of psychiatric disorders including schizophrenia, bipolar disorder, depression, attention deficit hyperactivity disorder (ADHD), and autism. By leveraging polygenic risk across these overlapping disorders, researchers hope to enhance predictive accuracy beyond traditional clinical assessments. Central to this genomic profiling is the adoption of the Blended Genome Exome (BGE) assay, a cost-effective sequencing technique designed to capture a broad swath of genetic variation.

The BGE assay distinguishes itself by balancing depth and breadth: it sequences the exome—the protein-coding portion of the genome—with high coverage around 30X, ensuring sensitive detection of rare, potentially pathogenic variants. Simultaneously, it surveys the remaining 98% of the genome at a low coverage between 1X and 3X, a calibrated depth optimized to detect common variants across diverse ancestries. This dual-faceted approach facilitates not only the detection of single nucleotide variants but also important structural alterations such as copy number variants, which have been implicated in psychiatric conditions.

Ensuring data integrity and reliability in such extensive sequencing endeavors is paramount. The AMP®SCZ team implements rigorous quality control (QC) measures encompassing multiple parameters: coverage metrics for both the exome and whole genome, per sample and variant call rates, contamination indices, and indicators of library preparation artifacts such as chimeric reads. Ancestry-specific filters based on median absolute deviations and genetic quality metrics like transition/transversion ratios and heterozygosity ensure outlier exclusion. Intriguingly, samples exhibiting discordance between reported biological sex and genetically inferred sex are systematically excluded to maintain dataset fidelity. Subsequent imputation of sequencing data, leveraging reference population genotypes, enables comprehensive polygenic score calculation rooted in large-scale genome-wide association studies (GWAS).

Beyond the genetic landscape, the study rigorously incorporates endocrine biomarkers, specifically salivary cortisol, owing to its well-documented involvement in stress-related psychosis risk. The collection protocol involves sampling saliva at three discrete time points over a two-hour window, with immediate freezing to preserve sample integrity. Cortisol quantification utilizes the Salimetrics enzyme-linked immunosorbent assay (ELISA) platform, performed consistently across two separate facilities using assays from the same manufacturer lot to preclude batch effects. Recognizing diurnal variations inherent to cortisol physiology, the measured values are adjusted accordingly along with other confounding variables. The averaged adjusted cortisol level is subsequently integrated into the risk prediction framework, enriching the biological dimensions of causality and prediction.

Proteomics, an indispensable pillar in the quest for biomarker discovery, is meticulously targeted to include proteins implicated in neuroinflammation, complement activation, coagulation pathways, and oxidative stress—processes intimately linked to psychotic pathophysiology. Furthermore, the analysis encompasses brain-derived blood proteins and molecules encoded by genes associated with schizophrenia susceptibility, alongside a comprehensive survey of blood-secreted proteins. To balance cost and analytical coverage, the project is evaluating two leading proteomic platforms: Olink and SomaScan, both commercial multiplex technologies with robust validation in clinical proteomics.

The Olink platform is predicated on a proximity extension assay that employs pairs of antibodies anchored to unique DNA oligonucleotides. Upon binding to the protein target, these oligonucleotides hybridize to form a DNA duplex, which is then amplified and quantified via sensitive real-time PCR methods. Contrastingly, SomaScan technology harnesses chemically modified, fluorescently labeled single-stranded DNA aptamers designed to bind target proteins with exceptional specificity and sensitivity. Both platforms can assay thousands of proteins spanning a dynamic concentration range congruent with plasma proteome complexity, and exhibit impressive reproducibility with minimal cross-reactivity—a critical factor for unbiased biomarker quantitation.

Data preprocessing takes a methodical path where raw proteomic measurements undergo manufacturer-recommended quality control filtering. The expectation is that most proteins demonstrate stable expression between baseline and two-month follow-up samples, enabling use of coefficient of variation distributions as a proxy for platform reproducibility. Analytical tools such as principal component analysis and Grubbs’s test help detect outliers, while assessments of hemolysis indicators, sample processing intervals, and physiological confounders like body mass index ensure biological validity of protein signals. Additional QC measures include assays targeting proteins sensitive to ex vivo blood cell or platelet activation—events known to artifactually inflate certain biomarker levels—thus safeguarding data authenticity.

The integration of these diverse biomarker modalities into clinically predictive models demands advanced computational strategies. Machine learning (ML) approaches, recognized for their potent pattern recognition and variable combination capabilities surpassing univariate analyses, are central to model development. However, the research team is acutely aware of the pitfalls posed by overfitting, where an algorithm may perform exquisitely on training datasets yet falter upon independent validation. To mitigate this, the methodological framework incorporates algorithmic safeguards explicitly designed to restrain overfitting tendencies.

Internal validation techniques such as cross-validation and bootstrap resampling provide repeated estimates of model generalizability by partitioning and re-sampling the dataset in multiple iterations. Such resampling mimics external population sampling variability, allowing robust performance metrics to be gleaned prior to prospective testing. Moreover, permutation testing serves as a critical statistical check by randomizing outcome labels and recalculating model accuracy thousands of times; if models outperform these null permutations, it strongly suggests true predictive signal rather than artifacts or chance correlations.

Through these multilayered strategies, the AMP®SCZ program anticipates constructing multivariable classifiers that forecast psychosis onset and related outcomes with unprecedented precision. The combinatory power of genetic, proteomic, and hormonal biomarkers, interpreted through sophisticated machine learning, promises to surmount current diagnostic limitations and elucidate the biological underpinnings of psychotic disorders.

The potential clinical impact of such predictive tools is transformative. Early identification of individuals at highest risk could enable targeted preventive interventions, optimized treatment selection, and personalized monitoring, fundamentally reshaping clinical psychiatry. Furthermore, the large-scale genetic and proteomic datasets generated will contribute to broader scientific understanding, facilitating discovery of novel therapeutic targets and pathways implicated in psychosis.

Future directions include validating these multivariate risk classifiers across diverse populations to ensure generalizability, refining biomarker panels for maximal cost-effectiveness and clinical utility, and integrating environmental and lifestyle data for comprehensive risk modeling. The AMP®SCZ’s commitment to open science and collaborative research accelerates this translational trajectory, setting a new benchmark for psychiatric biomarker development.

In sum, the Accelerating Medicines Partnership® Schizophrenia Program’s multifaceted biomarker exploration epitomizes a paradigm shift toward precision psychiatry. By harnessing the power of genomic sequencing, proteomic profiling, cortisol dynamics, and cutting-edge machine learning, this initiative seeks not only to predict psychosis risk with high fidelity but also to uncover the mechanistic biology that drives this enigmatic illness. The convergence of these technologies signals a hopeful horizon where mental illnesses are detected earlier, understood more deeply, and treated more effectively.

—

Subject of Research:
Biomarker development and risk prediction in psychosis through integration of genomic, proteomic, and endocrine data.

Article Title:
Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations.

Article References:
Perkins, D.O., Jeffries, C.D., Clark, S.R. et al. Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations. Schizophr 11, 78 (2025). https://doi.org/10.1038/s41537-025-00610-4

Image Credits: AI Generated

Psychosis, often characterized by hallucinations, delusions, and severe cognitive disturbances, traditionally emerges during late adolescence or early adulthood, profoundly impacting personal, social, and occupational functioning. However, the transition from a high-risk state to a diagnosable psychotic disorder is neither inevitable nor uniform, which complicates the development of preventative interventions. The PSYSCAN study pioneers an integrative approach to unravel this complexity by bringing together detailed clinical profiles, neuroimaging data, and cognitive assessments from a large cohort dispersed across multiple research sites internationally.

One of the most significant strengths of the PSYSCAN initiative lies in its scale and methodological rigor. By enlisting several centres, the study attains a diversity in participant demographics, environmental factors, and healthcare contexts, which enhances the generalizability of its findings. This distinction is critical because previous research often suffered from limited sample sizes and homogeneous populations, reducing the applicability of their conclusions across wider, more varied patient groups. Through harmonizing protocols across centres, PSYSCAN sets a new gold standard in multi-centre psychiatric research.

At the core of the PSYSCAN methodology is a comprehensive baseline evaluation, which comprises clinical interviews, neuropsychological testing, and advanced neuroimaging techniques such as magnetic resonance imaging (MRI). These measures allow researchers to capture a multidimensional snapshot of the high-risk individuals before any transition occurs. In particular, neuroimaging analyses focus on subtle structural and functional brain alterations that may signal an impending psychotic episode. Early detection of these neural markers is envisioned as a critical step toward timely intervention.

The clinical profiles gathered at baseline illuminate an intricate mosaic of symptoms and cognitive challenges faced by those at high risk. Many participants exhibited attenuated psychotic symptoms, including brief and mild hallucinations or delusions, along with mood disturbances and anxiety. Cognitive testing revealed deficits in verbal memory, attention, and executive function, highlighting the pervasive cognitive dysfunction associated with prodromal psychosis. These findings support a growing consensus that cognitive impairments precede and potentially predict psychotic breakdown.

Importantly, the PSYSCAN study goes beyond cross-sectional descriptions by monitoring clinical outcomes over time. Longitudinal follow-up permits the identification of trajectories within the high-risk population—some individuals may remit, others stabilize, while a subset converts to full psychosis. Understanding the factors that drive these divergent paths underpins personalized medicine approaches, enabling clinicians to tailor interventions based on probabilistic risk patterns rather than a one-size-fits-all model. This paradigm shift could mitigate the long-term disability associated with psychotic disorders.

One particularly innovative facet of the PSYSCAN research is the integration of machine learning algorithms into data analysis pipelines. By leveraging artificial intelligence, the team can sift through vast, multidimensional data sets to discern patterns imperceptible to human observers. These computational models hold promise for developing predictive tools that identify individuals most likely to transition to psychosis, thereby optimizing resource allocation and preventive care. The fusion of data science with clinical psychiatry heralds a transformative era in mental health research.

Moreover, the multi-modal design of PSYSCAN addresses a critical challenge in psychiatry: the heterogeneity of psychotic disorders. Different patients manifest distinct symptom clusters, neurobiological alterations, and cognitive profiles. By concurrently analyzing clinical, cognitive, and imaging data, the study enhances the precision of diagnostic algorithms and fosters the discovery of subtypes within the psychosis spectrum. Such granularity is essential for unraveling the pathophysiological mechanisms underlying psychosis and developing targeted therapeutics.

In addition to its scientific contributions, the PSYSCAN study underscores the importance of international collaboration and data sharing. Psychiatric disorders transcend geographic and cultural boundaries, yet research efforts often remain siloed. By fostering cooperative networks and standardized protocols, PSYSCAN not only accelerates knowledge generation but also democratizes access to cutting-edge diagnostic and therapeutic tools across different healthcare systems. This collaborative spirit sets a precedent for future studies in psychiatric illnesses.

Ethical considerations also permeate the PSYSCAN framework, particularly given the sensitive nature of predicting psychosis onset. Researchers meticulously balance the benefits of early identification against the risks of labeling and potential stigmatization. The study incorporates informed consent, confidentiality safeguards, and ethical oversight to ensure participants’ welfare. These protocols exemplify responsible research practices that respect patients’ dignity while advancing scientific discovery, a vital aspect of clinical investigations involving vulnerable populations.

Furthermore, the clinical high-risk construct used to select participants for PSYSCAN represents an evolving concept within psychiatry. It denotes individuals who exhibit subthreshold psychotic symptoms or genetic vulnerabilities but have yet to develop clear psychosis. This intermediate state provides a vital window for intervention. However, the criteria remain fluid as new empirical findings refine our understanding of at-risk states. PSYSCAN contributes essential data to this ongoing discourse, informing future revisions of clinical guidelines.

The potential impact of PSYSCAN extends beyond academic circles into clinical practice and public health policy. By establishing robust biomarkers and predictive models, the findings could inform screening programs in primary care and community settings. Early detection coupled with evidence-based interventions could reduce the incidence of full-blown psychosis, ease the burden on mental health services, and improve patients’ quality of life. Policymakers might draw on these insights to design preventative mental health initiatives and allocate funding more strategically.

Technologically, the advanced neuroimaging protocols employed are at the forefront of current capabilities. High-resolution structural MRI scans elucidate cortical thickness, gray matter volume, and subcortical structures involved in psychosis. Functional MRI data provide insights into brain network connectivity and activity patterns during cognitive tasks or rest. These neural markers serve both as indicators of disease risk and as potential targets for novel treatments, such as neuromodulation or cognitive training, which could one day alter the course of psychotic illnesses.

The PSYSCAN findings also echo a growing recognition that psychosis is not merely a disorder of isolated brain regions but a system-wide dysregulation involving complex neural circuits. Disruptions in networks governing salience processing, executive control, and sensory integration may underpin the symptomatic manifestations seen in high-risk individuals. By mapping these network abnormalities longitudinally, researchers gain critical clues about the temporal dynamics of psychosis onset and progression, informing theoretical models of mental illness.

In summary, the PSYSCAN multi-centre study represents a landmark in psychiatric research, marrying comprehensive clinical assessment and cutting-edge neuroscience to tackle one of mental health’s biggest challenges. Its robust baseline characterizations and ongoing follow-up data provide a rich resource for elucidating the pathogenesis of psychosis and refining early intervention strategies. As PSYSCAN’s findings gain traction, they hold the promise of transforming how clinicians identify, predict, and ultimately prevent psychotic disorders, ushering a new era of precision psychiatry.

Subject of Research: Clinical high risk for psychosis sample; baseline characteristics and clinical outcomes.

Article Title: PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample.

Article References:
Tognin, S., Vieira, S., Oliver, D. et al. PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample. Schizophr 11, 66 (2025). https://doi.org/10.1038/s41537-025-00598-x

Image Credits: AI Generated